| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C15H13FN2 |
| Molar mass | 240.281 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Raseglurant (INN; development codeADX-10059) is anegative allosteric modulator of themGlu5 receptor andderivative ofMPEP which was under development byAddex Therapeutics for the treatment ofmigraine,gastroesophageal reflux disease, anddental anxiety.[1][2][3] It reachedphase IIclinical trials for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs ofhepatotoxicity in patients with long-term use.[3][4][5]
Thisdrug article relating to thenervous system is astub. You can help Wikipedia byadding missing information. |